Acceleron Pharma

Release Summary

Acceleron Pharma announced that data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC) will be presented at ASCO 2015

Acceleron Pharma